国新健康：预计2025年全年营业收入3.51亿元

Core Viewpoint - Guoxin Health expects a total operating revenue of 351 million yuan for the year 2025, maintaining stability compared to the previous year [1] Group 1: Financial Performance - For the first three quarters of 2025, the company's main revenue was 170 million yuan, a year-on-year decrease of 14.87% [2] - The net profit attributable to shareholders was -138 million yuan, a year-on-year decline of 347.32% [2] - The net profit after deducting non-recurring gains and losses was -138 million yuan, a year-on-year decrease of 27.09% [2] - In Q3 2025, the company's single-quarter main revenue was 74.87 million yuan, a year-on-year increase of 19.26% [2] - The single-quarter net profit attributable to shareholders was -39.34 million yuan, a year-on-year decline of 193.59% [2] - The single-quarter net profit after deducting non-recurring gains and losses was -39.37 million yuan, a year-on-year decrease of 29.67% [2] - The company's debt ratio stood at 37.02% [2] - Investment income was 16.57 million yuan, while financial expenses amounted to 6.53 million yuan [2] - The gross profit margin was -5.15% [2] Group 2: Strategic Focus - The company is aligning its operations with the "Healthy China" initiative and the "Three Medical Collaborations" reform, focusing on health data integration and digital transformation [1] - The strategic focus includes comprehensive management services for medical insurance funds, medical quality and safety services, and health service innovation [1] - The company aims to leverage data value and actively pursue investment collaborations to support the national strategy for "Healthy China" [1] Group 3: Asset Impairment - The increase in losses is primarily due to expected impairment of trading financial assets, specifically a 99.01% partnership interest in Shenzhou Borui (Shenzhen) Investment Enterprise [1] - The decline in operating performance of Shenzhou Medical Technology Co., Ltd., in which Shenzhou Borui holds a 7.66% stake, is anticipated to result in a fair value loss of approximately 260 million yuan on the company's trading financial assets [1]